Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

ANI Pharmaceuticals, Inc. (ANIP) vs HUTCHMED (China) Limited Sponsored ADR (HCM)

ANI Pharmaceuticals, Inc. and HUTCHMED (China) Limited Sponsored ADR are both Drug Manufacturers Specialty & Generic companies. HUTCHMED (China) Limited Sponsored ADR is the larger, with a market value of $2.4B against $1.7B — 1.4× the size. HUTCHMED (China) Limited Sponsored ADR has negative trailing earnings, so its P/E is not meaningful; ANI Pharmaceuticals, Inc. trades at 15.3×. HUTCHMED (China) Limited Sponsored ADR grew revenue faster over the last twelve months: 245.2% against 30.9%. ANI Pharmaceuticals, Inc. has the higher net margin (11.0% vs −23.6%) and the higher return on invested capital (11.3% vs 0.00%). Across the 17 metrics below, ANI Pharmaceuticals, Inc. leads on 11 and HUTCHMED (China) Limited Sponsored ADR on 6.

Valuation

Metric ANIP HCM Drug Manufacturers Specialty & Generic median
P/E 15.32 n/m 20.14
P/S 1.60 n/m 2.25
P/B 2.62 n/m 1.90
Price to free cash flow 9.35 n/m 16.54
EV/EBITDA 7.62 0.38 12.29
EV/Sales 1.84 (0.13) 2.56
Earnings yield 6.53% (21.11%) (2.99%)
Free cash flow yield 10.70% 0.00% 0.00%

Profitability

Metric ANIP HCM Drug Manufacturers Specialty & Generic median
Gross margin 60.40% 44.40% 53.94%
Operating margin 15.37% 0.00% 0.00%
Net margin 11.04% (23.63%) 0.00%
Free cash flow margin 17.12% 0.00% 0.00%
Return on equity 20.88% 0.00% (0.40%)
Return on assets 7.61% 0.00% (3.32%)
Return on invested capital 11.30% 0.00% 0.00%

Growth

Metric ANIP HCM Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 30.90% 245.17% 10.01%
EPS growth (last fiscal year) 419.23% 1,090.91% —
Revenue growth, 5-year CAGR 33.48% 19.20% 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ANIP HCM Drug Manufacturers Specialty & Generic median
Debt to equity 1.02 0.07 0.05
Current ratio 2.91 5.64 2.31
Net debt to EBITDA 1.59 49.29 0.85

Dividend

Metric ANIP HCM Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric ANIP HCM Drug Manufacturers Specialty & Generic median
Market cap 1.70b 2.43b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack